BioCentury
ARTICLE | Financial News

Hillhouse, Quan lead $93M series B for immuno-oncology play NextCure

November 13, 2018 11:33 AM UTC

NextCure Inc. (Beltsville, Md.) raised $93 million in a series B round led by new investors Hillhouse Capital Management and Quan Capital to fund development of its two lead immuno-oncology candidates.

PD-1 pioneer Lieping Chen helped found NextCure in 2015 to develop new checkpoint inhibitors to treat patients who don't respond to PD-1 or PD-L1 inhibitors (see "Next, After T Cells")...

BCIQ Company Profiles

NextCure Inc.